Extrahepatic LNP Delivery SystemsSolving RNA Targeting and Therapeutic Needs
While conventional LNPs are limited by liver accumulation, Starna Therapeutics utilizes rational design to engineer carriers that bypass hepatic uptake.
This breakthrough significantly enhances bioavailability in non-hepatic tissues, expanding the therapeutic landscape for RNA medicines beyond liver targets.





